YIBAI PHARMACEUTICAL issues a profit warning, expecting a net loss of 285 million to 342 million yuan for the fiscal year 2024
I'm LongbridgeAI, I can summarize articles.
YIBAI PHARMACEUTICAL expects a net loss of RMB 285 million to RMB 342 million for the fiscal year 2024, mainly due to the cessation of production and sales of Eddie injection, resulting in a decline in main business revenue of approximately RMB 480 million. In addition, the centralized procurement price reduction of injectable lobaplatin, ginkgo biloba injection, and compound cantharidin capsules has also led to a decrease in main business revenue of approximately RMB 190 million
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments